Literature Overview of the IL-17 Inhibition from Psoriasis to COVID-19
Yulin Zou, Zudong Meng Department of Dermatology, Renmin Hospital, Hubei University of Medicine, Shiyan City, People’s Republic of ChinaCorrespondence: Zudong Meng Email zylmch1007@hbmu.edu.cnAbstract: The COVID-19 pandemic has posed a serious problem for drug anti-viral efficacy in combat...
Guardado en:
Autores principales: | Zou Y, Meng Z |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/c17d6b59e6564653a2e5d1bde94e5ef0 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Generation and characterization of ixekizumab, a humanized monoclonal antibody that neutralizes interleukin-17A
por: Liu L, et al.
Publicado: (2016) -
Inflammatory Cytokine: IL-17A Signaling Pathway in Patients Present with COVID-19 and Current Treatment Strategy
por: Shibabaw T
Publicado: (2020) -
Clinical Evaluation of Risankizumab-rzaa in the Treatment of Plaque Psoriasis
por: Reddy V, et al.
Publicado: (2020) -
Role of maternal serum interleukin 17 in preeclampsia: diagnosis and prognosis
por: El Shahaway AA, et al.
Publicado: (2019) -
IL-33/ST2 Axis Deficiency Exacerbates Hepatic Pathology by Regulating Treg and Th17 Cells in Murine Schistosomiasis Japonica
por: Bai Y, et al.
Publicado: (2021)